Bristol-Myers Squibb and BioMotiv have teamed up to create Anteros Pharmaceuticals, a company that will focus on developing a new class of drugs for fibrotic and other inflammatory diseases, the companies said Feb. 4.
BioMotiv, a company focused on turning breakthrough discoveries from research institutions into drugs, will work with Yale University and will be solely responsible for research and development for Anteros.
Bristol-Myers will contribute the IP, data and reagents for Anteros.
Anteros is the first of several companies Biomotiv and Bristol-Myers plan to form.
Read the full news release here.